Management of recurrent retroperitoneal sarcoma

Authors

  • David E. Gyorki MD,

    Corresponding author
    1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    • Correspondence to: Murray F. Brennan, MD, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Fax: 212-794-5845. E-mail: brennanm@mskcc.org

    Search for more papers by this author
  • Murray F. Brennan MD

    1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author

  • Conflict of interest: The authors have no disclosures.

Abstract

Approximately 15% of soft tissue sarcomas are retroperitoneal. The occult location and anatomic complexity results in local recurrences in the majority of patients. Predictors of recurrence include histological subtype, completeness of resection, and the hospital case volume. The most significant predictor of outcome following local recurrence is the resectability of the recurrent disease. An understanding of the implication of tumor biology on outcomes is essential in determining optimal management for patients with recurrent retroperitoneal sarcoma. J. Surg. Oncol. 2014 109:53–59. © 2013 Wiley Periodicals, Inc.

Ancillary